Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
Recruiting now · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Menopause, Premature, Menopause Related Conditions, Menopausal Syndrome, Premature Ovarian Failure, Ovarian Failure, Premature
In brief
Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve patients' hormonal profile in patients presenting with POI.
Key facts
- Study ID
- NCT04031456
- Run by
- Genesis Athens Clinic
- People needed
- 100
- Starts
- 2019-07-30
- Expected to finish
- 2028-07-30
- Last updated by the study team
- 2026-07-08
Who can join
Age: 25 and older, up to 39. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Age < 40 years, presenting with amenorrhea or menstrual cycle irregularities for at least four months, and elevated FSH levels >25 IU/L recorded on two occasions >4 weeks apart
- Normal Karyotype: 46, XX
- Discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.
- Willing to comply with study requirements
You may not qualify if…
- Any pathological disorder related to reproductive system anatomy
- AMH > 8 pmol/L
- Endometriosis
- Adenomyosis
- Fibroids and adhesions
- Infections in reproductive system
- Current or previous diagnosis of cancer in reproductive system
- History of familiar cancer in reproductive system
- Severe male factor infertility
- Prior referral for PGT
- Ovarian inaccessibility
- Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)
- BMI>30 kg/m2 or BMI<18.5 kg/m2
- Systematic autoimmune disorders
Where it is running
- Genesis AC — Athens, Greece (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.